All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

An expert panel hosted by

The Lymphoma Hub logo and the Multiple Myeloma Hub logo

Sequencing immune-based therapies in B-cell malignancies

with Ulric Jäger, Sagar Lonial, and Krina Patel

Saturday, June 15 | 18:00-19:30 CEST

Register now

This independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.

  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2024-06-19T15:53:10.000Z

What is the role of treatment line and duration in patients with LBCL treated with CAR T cells?

Jun 19, 2024
Share:

During the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Lymphoma Hub spoke to Stefano Luminari, University of Modena and Reggio Emilia, Modena, IT. We asked, What is the role of treatment line and duration in patients with large B-cell lymphoma (LBCL) treated with chimeric antigen receptor (CAR) T cells?

What is the role of treatment line and duration in patients with LBCL treated with CAR T cells?

First, Luminari highlights the improved outcomes shown with axicabtagene ciloleucel and lisocabtagene maraleucel when compared with standard therapies in the second-line setting, and the clinical implications of these results. He also discusses the impact of the earlier use of CAR T-cell therapy and the importance of identifying patients who have a high risk of relapse who may benefit from timely CAR T-cell therapy. He concludes that CAR T-cell therapy, particularly axicabtagene ciloleucel, represents a major advancement for patients with relapsed LBCL and raises the importance of detecting early signs of relapse.  

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox